Value Assessment And Decision Making In The Face Of Uncertainty
In the penultimate Health Affairs Forefront series, Mark Linthicum, Richard Chapman, and Jeroen Jansen address uncertainty in healthcare value assessment and decision-making and identify the following opportunities for change: We need a more dynamic approach to value assessment. Economic models should include both parameter and structural uncertainty to fully characterize the implications for decision-making. Gaps […]
Frequently Asked Questions about the IVI Draft Protocol for Major Depressive Disorder
Introduction The Innovation and Value Initiative welcomes public comments on its draft model protocol on major depressive disorder. The deadline to submit comments has been extended to Tuesday, January 25th. This economic model currently under development is part of IVI’s Open-Source Value Project (OSVP). You can learn more about the model protocol through IVI’s introductory […]
Value In Medicaid, Part 2: Challenges Concerning Health-Related Social Needs
In the second of a two-part Health Affairs post, Dr. Anish Mahajan writes about several challenges concerning health-related social needs in the journey to value in Medicaid. He addresses challenges including use of social needs screening tools, case management infrastructure and workflow development. He also cites the need for further research to better align the health and social sectors […]
Value In Medicaid, Part 1: Administrative, Regulatory, And Financial Challenges
Part 1 in a two-part blog series by Anish P. Mahajan, MD, the Chief Executive Officer of Harbor-UCLA Medical Center and Associate Dean at UCLA-Geffen School of Medicine, examines the administrative, regulatory, and financial challenges to achieving value in the Medicaid program. Read the full article here. About the Blog Series The Innovation and Value […]
Harmonization Of Health Technology Assessment Across The European Union: Lessons For The United States
In the latest piece of the IVI and Health Affairs blog series, Rosanna Tarricone and James Robinson compare the U.S. HTA landscape with experiences in Europe, using it to draw some lessons learned. The authors argue that we should be careful about any effort to centralize HTA. Instead, they recommend that we work on ways […]
Pursuing Health Care Value Post-COVID-19: Keep The Focus On Patients
At the midpoint of the Health Affairs and IVI blog series, PCORI’s Nakela Cook discusses an essential lesson from the pandemic that must be applied to clinical research, healthcare delivery, and public health – patients must help drive the calculus that policymakers apply to building a more equitable, affordable healthcare system that delivers optimal outcomes. […]
How Current Cost-Effectiveness Analyses Distort Drug Development Priorities
In the latest post in our ongoing series with Health Affairs blog, Soeren Mattke takes on the relationship value assessment and innovation of new therapies. He argues that cost-effectiveness analysis, one of the most common methods for economic assessments, may be distorting the incentives for investment in medical research and drug development. Specifically, he explains […]
IVI MEMBER SPOTLIGHT: Danny van Leeuwen
This year we are pleased to welcome Danny van Leeuwen as a new member of the Innovation and Value Initiative. Danny is the host of HealthHats, a podcast and blog that helps people learn on the journey towards health. We were delighted that he took the time to speak with our own Jennifer Bright on […]
Bolstering Our Ability To Value Health Technology: A Few Less-Considered Issues
AcademyHealth’s Michael E. Gluck authors the next in the IVI and Health Affairs blog series. He describes historical public efforts to implement HTA and how it “intersects with all of the major challenges facing US health care: cost, quality, access, equity, social determinants, and the tensions between the country’s dual commitments to innovation and health […]
Fair Prices Should Lead To Fair Access: Why Is The Grand Bargain So Hard?
In a new post in our ongoing blog series with Health Affairs, ICER’s Sarah Emond discusses the challenge of achieving a “grand bargain” in which fair prices and fair access provide optimal benefits to both patients and the health system. At the root, she argues, is the different and sometimes-conflicting perspectives, objectives, and incentives of the […]